Ironwood Pharmaceuticals, Inc.

DB:I76 Stock Report

Market Cap: €715.4m

Ironwood Pharmaceuticals Management

Management criteria checks 3/4

Ironwood Pharmaceuticals' CEO is Tom McCourt, appointed in Mar 2021, has a tenure of 3.83 years. total yearly compensation is $7.58M, comprised of 11% salary and 89% bonuses, including company stock and options. directly owns 0.32% of the company’s shares, worth €2.29M. The average tenure of the management team and the board of directors is 3.4 years and 5.8 years respectively.

Key information

Tom McCourt

Chief executive officer

US$7.6m

Total compensation

CEO salary percentage11.0%
CEO tenure3.8yrs
CEO ownership0.3%
Management average tenure3.4yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Tom McCourt's remuneration changed compared to Ironwood Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$2m

Jun 30 2024n/an/a

US$9m

Mar 31 2024n/an/a

-US$1b

Dec 31 2023US$8mUS$834k

-US$1b

Sep 30 2023n/an/a

-US$952m

Jun 30 2023n/an/a

-US$917m

Mar 31 2023n/an/a

US$182m

Dec 31 2022US$8mUS$805k

US$175m

Sep 30 2022n/an/a

US$168m

Jun 30 2022n/an/a

US$173m

Mar 31 2022n/an/a

US$527m

Dec 31 2021US$9mUS$732k

US$528m

Sep 30 2021n/an/a

US$530m

Jun 30 2021n/an/a

US$509m

Mar 31 2021n/an/a

US$143m

Dec 31 2020US$3mUS$576k

US$106m

Sep 30 2020n/an/a

US$111m

Jun 30 2020n/an/a

US$97m

Mar 31 2020n/an/a

US$84m

Dec 31 2019US$5mUS$511k

US$59m

Sep 30 2019n/an/a

US$19m

Jun 30 2019n/an/a

-US$153m

Mar 31 2019n/an/a

-US$173m

Dec 31 2018US$2mUS$465k

-US$194m

Compensation vs Market: Tom's total compensation ($USD7.58M) is above average for companies of similar size in the German market ($USD1.41M).

Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.

CEO

Tom McCourt (67 yo)

3.8yrs

Tenure

US$7,583,270

Compensation

Mr. Thomas A. McCourt, also known as Tom, serves as Director at Pliant Therapeutics, Inc. since March 08, 2023. He serves as Chief Executive Officer and Director of Ironwood Pharmaceuticals, Inc. since Jun...

Leadership Team

NamePositionTenureCompensationOwnership
Thomas McCourt
CEO, Principal Financial Officer & Director3.8yrsUS$7.58m0.32%
€ 2.3m
John Minardo
Senior VP3.4yrsUS$2.44m0.079%
€ 568.6k
Michael Shetzline
Chief Medical Officer6yrsUS$2.60m0.16%
€ 1.1m
Ronald Silver
Corporate Controller & Principal Accounting Officer5.8yrsno data0.042%
€ 303.7k
Rosario Lobrutto
VP & Global Head of Technical Operationsless than a yearno datano data
Greg Martini
Vice President of Strategic Finance & Investor Relationsno datano datano data
Beth Calitri
VP of Corporate Communications & Media Relations3yrsno datano data
Mike Nanfito
Vice President of Sales & Sales Excellence3.3yrsno datano data
Susanna Huh
VP & Head of Clinical Development2.3yrsno datano data
Matt Roache
Director of Investor Relationsno datano datano data

3.4yrs

Average Tenure

56.5yo

Average Age

Experienced Management: I76's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Thomas McCourt
CEO, Principal Financial Officer & Director3.6yrsUS$7.58m0.32%
€ 2.3m
Jay Shepard
Independent Director4.1yrsUS$300.71k0.079%
€ 565.7k
Perry Halushka
Member of Pharmaceuticals Advisory Committeeno datano datano data
Alexander Denner
Independent Director4.2yrsUS$300.69k0.098%
€ 699.0k
Mark Currie
Independent Director5.8yrsUS$300.71k0.36%
€ 2.5m
Andrew Dreyfus
Independent Director8.8yrsUS$310.71k0.12%
€ 841.5k
Michael Mendelsohn
Member of Pharmaceutical Advisory Committee7.9yrsno datano data
Catherine Moukheibir
Independent Director5.8yrsUS$310.69k0.046%
€ 326.1k
Julie McHugh
Independent Chairman of the Board10.9yrsUS$335.71k0.10%
€ 732.4k
Marla Kessler
Independent Director5.8yrsUS$300.71k0.076%
€ 540.4k
Jon Duane
Independent Director5.8yrsUS$305.71k0.091%
€ 649.7k

5.8yrs

Average Tenure

65yo

Average Age

Experienced Board: I76's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 09:34
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ironwood Pharmaceuticals, Inc. is covered by 36 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuAegis Capital Corporation
Geoffrey MeachamBarclays
Patrick TrucchioBerenberg